| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
ORIGINAL RESEARCH COMMUNICATION |
From the Southern California Evidence-Based Practice Center, which includes RAND Health, Santa Monica, CA (CHM, WAM, SJN, RHG, WT, LGH, IMG, SR, PK, and SCM); the Greater Los Angeles VA Healthcare System Divisions of Rheumatology (CHM) and Gastroenterology (IMG), Los Angeles, CA; Clinical Decision Making and Healthcare, Toronto General Research Institute, Toronto General Hospital, Toronto, Ontario, Canada (JP); and the Institute of Medical Science, Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada (JP)
Background: n–3 Fatty acids are purported to have health effects in patients with inflammatory bowel disease (IBD), but studies have reported mixed results.
Objective: We aimed to synthesize published and unpublished evidence to determine estimates of the effect of n–3 fatty acids on clinical outcomes in IBD and whether n–3 fatty acids modify the effects of or need for treatment with other agents.
Design: Computerized databases were searched for studies of n–3 fatty acids in immune-mediated diseases from 1966 to 2003. We also contacted experts in the nutraceutical industry to identify unpublished studies; however, none were identified.
Results: Reviewers identified 13 controlled trials that assessed the effects of n–3 fatty acids on clinical, sigmoidoscopic, or histologic scores; rates of induced remission or relapse; or requirements for steroids and other immunosuppressive agents in Crohn disease or ulcerative colitis. Most clinical trials were of good quality. Fewer than 6 were identified that assessed the effects of n–3 fatty acids on any single outcome of clinical, endoscopic, or histologic scores or remission or relapse rates. Consistent across 3 studies was the finding that n–3 fatty acids reduce corticosteroid requirements, although statistical significance was shown in only 1 of these studies.
Conclusion: The available data are insufficient to draw conclusions about the effects of n–3 fatty acids on clinical, endoscopic, or histologic scores or remission or relapse rates.
Key Words: n–3 Fatty acids • inflammatory bowel disease
This article has been cited by other articles:
|
|
 |
|
  J. W. Fetterman Jr. and M. M. Zdanowicz Therapeutic potential of n-3 polyunsaturated fatty acids in disease Am. J. Health Syst. Pharm., July 1, 2009; 66(13): 1169 - 1179. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R Marion-Letellier, P Dechelotte, M Iacucci, and S Ghosh Dietary modulation of peroxisome proliferator-activated receptor gamma Gut, April 1, 2009; 58(4): 586 - 593. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. Biasi, C. Mascia, and G. Poli The contribution of animal fat oxidation products to colon carcinogenesis, through modulation of TGF-{beta}1 signaling Carcinogenesis, May 1, 2008; 29(5): 890 - 894. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. O. Clarke and G. E. Mullin A Review of Complementary and Alternative Approaches to Immunomodulation Nutr Clin Pract, February 1, 2008; 23(1): 49 - 62. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Gura, R. Strijbosch, S. Arnold, C. McPherson, and M. Puder The Role of an Intravenous Fat Emulsion Composed of Fish Oil in a Parenteral Nutrition-Dependent Patient With Hypertriglyceridemia Nutr Clin Pract, December 1, 2007; 22(6): 664 - 672. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. M Balk, T. A Horsley, S. J Newberry, A. H Lichtenstein, E. A Yetley, H. M Schachter, D. Moher, C. H MacLean, and J. Lau A collaborative effort to apply the evidence-based review process to the field of nutrition: challenges, benefits, and lessons learned Am. J. Clinical Nutrition, June 1, 2007; 85(6): 1448 - 1456. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. S. Chapkin, L. A. Davidson, L. Ly, B. R. Weeks, J. R. Lupton, and D. N. McMurray Immunomodulatory Effects of (n-3) Fatty Acids: Putative Link to Inflammation and Colon Cancer J. Nutr., January 1, 2007; 137(1): 200S - 204S. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. L. Jensen Inflammation as the Key Interface of the Medical and Nutrition Universes: A Provocative Examination of the Future of Clinical Nutrition and Medicine JPEN J Parenter Enteral Nutr, September 1, 2006; 30(5): 453 - 463. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Lee, K. M. Gura, S. Kim, D. A. Arsenault, B. R. Bistrian, and M. Puder Current Clinical Applications of {Omega}-6 and {Omega}-3 Fatty Acids Nutr Clin Pract, August 1, 2006; 21(4): 323 - 341. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. J Deckelbaum and S. R Akabas n-3 Fatty acids and cardiovascular disease: navigating toward recommendations Am. J. Clinical Nutrition, July 1, 2006; 84(1): 1 - 2. [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
